EP PerMed 2027: cell and gene therapy for personalised medicine
EP PerMed partnership and national/regional funders, co-funded by the EU · Amount and funding rate depend on the national or regional funder; the total call budget is not an individual grant
Eligible companies: EP PerMed participating countries: AT, BE, CA, CZ, EE, FI, FR, DE, HU, IE, IT, LV, LT, LU, NO, PL, PT, RO, SK, ES, SE, NL, TR; IL to be confirmed — geographic conditions to be confirmed
Company eligibility depends on the national or regional funder: in Belgium check VLAIO (Flanders) or SPW (Wallonia). Israeli participation remains unconfirmed; an academic funder’s presence does not mean an SME can receive funding.
Who can apply
At least 3 independent partners from 3 participating EU Member States or associated countries; SMEs and industry eligible under their funder’s rules alongside academic or clinical teams. An early-career researcher must be a principal investigator in the consortium.
Good to know
Summary: EP PerMed 2027: cell and gene therapy for personalised medicine. Published on 4 November 2026. Pre-proposal due 20 January 2027 at 14:00; full proposal due 25 May 2027 at 14:00 Brussels time. Innovative cell/gene therapies with preliminary data and a pathway towards clinical use; phase I–IV clinical trials excluded. Maximum duration 3 years. In Belgium, check VLAIO/SPW and regional rules before applying; additional regional forms may be required. Difficulty (editorial assessment): High — international consortium and specialised biomedical proposal. For you if… At least 3 independent partners from 3 participating EU Member States or associated countries; SMEs and industry eligible under their funder’s rules alongside academic or clinical teams. An early-career researcher must be a principal investigator in the consortium.
The call, in plain language
What the call funds
This call funds research on cell and gene therapies within personalised medicine. Projects must have preclinical data and prepare a path towards clinical application; phase I–IV clinical trials are excluded.
Who can apply
At least 3 independent partners from 3 participating EU Member States or associated countries; SMEs and industry eligible under their funder’s rules alongside academic or clinical teams. An early-career researcher must be a principal investigator in the consortium.
How much
Amount and funding rate depend on the national or regional funder; the total call budget is not an individual grant. Call budget: Approximately €38M across the transnational call.
Steps and dates
Pre-proposal by 20 January 2027 at 14:00, then full proposal by 25 May 2027 at 14:00 (Brussels). Projects last at most three years. Allow for national or regional funder formalities as well.
Check before applying
The approximately €38M is for the whole call. Each partner’s ceiling, rate and eligibility depend on its funder; companies are not automatically eligible in every region.
The rules that count are those on the official page. Checked on 6 November 2026
Independent site, not affiliated with the EU or any government; information provided without warranty, always check the official source.
Other calls in the same country or region
Integrated Surveillance mechanism: Regional Cable hubs
European Commission
OASIS: fifth support call for offshore-energy SMEs
Interreg North Sea — OASIS consortium
AI chip demonstrators
Chips Joint Undertaking (Chips JU)
